Do analysts prefer LNAI or CING?

Cingulate has a consensus price target of $27.33, suggesting a potential upside of 474.23%. Given Cingulate's stronger consensus rating and higher probable upside, analysts clearly believe Cingulate is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cingulate 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher earnings & valuation, LNAI or CING?

Lunai Bioworks is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A Cingulate N/A N/A -$22.45M -$4.23 N/A

Is LNAI or CING more profitable?

Cingulate's return on equity of -365.15% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% Cingulate N/A -365.15% -158.55%

Which has better earnings and valuation, ACRV or LNAI?

Lunai Bioworks is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acrivon Therapeutics N/A N/A -$77.90M -$2.00 N/A Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A

Is ACRV or LNAI more profitable?

Acrivon Therapeutics' return on equity of -64.43% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Acrivon Therapeutics N/A -64.43% -57.08% Lunai Bioworks N/A -1,243.45% -1,617.76%

Do analysts rate KALA or LNAI?

KALA BIO currently has a consensus target price of $1,018.75, suggesting a potential upside of 39,850.98%. Given KALA BIO's stronger consensus rating and higher probable upside, research analysts clearly believe KALA BIO is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KALA BIO 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, KALA or LNAI?

Lunai Bioworks is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio KALA BIO N/A N/A -$26.98M -$96.14 N/A Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A

Is KALA or LNAI more profitable?

Lunai Bioworks' return on equity of -1,243.45% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -1,336.10% -94.85% Lunai Bioworks N/A -1,243.45% -1,617.76%

Do analysts rate EXOZ or LNAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is EXOZ or LNAI more profitable?

eXoZymes' return on equity of -220.63% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% Lunai Bioworks N/A -1,243.45% -1,617.76%

Do analysts rate LNAI or BYSI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LNAI or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% BeyondSpring N/A N/A -14.00%

Lunai Bioworks (LNAI) Competitors

$3.56 +0.13 (+3.79%)

Closing price 06/25/2026 04:00 PM Eastern

Extended Trading

$3.46 -0.10 (-2.67%)

As of 06/25/2026 07:23 PM Eastern

Compare

LNAI vs. CING, ACRV, KALA, EXOZ, and BYSI

Should you buy Lunai Bioworks stock or one of its competitors? MarketBeat compares Lunai Bioworks with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lunai Bioworks include Cingulate (CING), Acrivon Therapeutics (ACRV), KALA BIO (KALA), eXoZymes (EXOZ), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical products" industry.

How does Lunai Bioworks compare to Cingulate?

Lunai Bioworks (NASDAQ:LNAI) and Cingulate (NASDAQ:CING) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Cingulate has a consensus price target of $27.33, suggesting a potential upside of 474.23%. Given Cingulate's stronger consensus rating and higher probable upside, analysts clearly believe Cingulate is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cingulate's return on equity of -365.15% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
Cingulate	N/A	-365.15%	-158.55%

Lunai Bioworks is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A

Lunai Bioworks has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, Cingulate has a beta of -0.85, meaning that its share price is 185% less volatile than the broader market.

In the previous week, Cingulate had 2 more articles in the media than Lunai Bioworks. MarketBeat recorded 3 mentions for Cingulate and 1 mentions for Lunai Bioworks. Cingulate's average media sentiment score of 1.33 beat Lunai Bioworks' score of 0.00 indicating that Cingulate is being referred to more favorably in the news media.

Company	Overall Sentiment
Lunai Bioworks	Neutral
Cingulate	Positive

71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by company insiders. Comparatively, 5.3% of Cingulate shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Cingulate beats Lunai Bioworks on 10 of the 13 factors compared between the two stocks.

How does Lunai Bioworks compare to Acrivon Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Lunai Bioworks is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A

Acrivon Therapeutics presently has a consensus target price of $11.67, suggesting a potential upside of 638.40%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Acrivon Therapeutics is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Acrivon Therapeutics and Acrivon Therapeutics both had 1 articles in the media. Acrivon Therapeutics' average media sentiment score of 1.87 beat Lunai Bioworks' score of 0.00 indicating that Acrivon Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Acrivon Therapeutics	Very Positive
Lunai Bioworks	Neutral

71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are held by institutional investors. 10.5% of Acrivon Therapeutics shares are held by company insiders. Comparatively, 0.5% of Lunai Bioworks shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Acrivon Therapeutics has a beta of 1.89, suggesting that its share price is 89% more volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

Acrivon Therapeutics' return on equity of -64.43% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-64.43%	-57.08%
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%

Summary

Acrivon Therapeutics beats Lunai Bioworks on 11 of the 12 factors compared between the two stocks.

How does Lunai Bioworks compare to KALA BIO?

KALA BIO (NASDAQ:KALA) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

24.6% of KALA BIO shares are held by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are held by institutional investors. 2.2% of KALA BIO shares are held by insiders. Comparatively, 0.5% of Lunai Bioworks shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Lunai Bioworks' return on equity of -1,243.45% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-1,336.10%	-94.85%
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%

Lunai Bioworks is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A

In the previous week, KALA BIO and KALA BIO both had 1 articles in the media. KALA BIO's average media sentiment score of 1.87 beat Lunai Bioworks' score of 0.00 indicating that KALA BIO is being referred to more favorably in the media.

Company	Overall Sentiment
KALA BIO	Very Positive
Lunai Bioworks	Neutral

KALA BIO has a beta of -2.4, suggesting that its stock price is 340% less volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

KALA BIO currently has a consensus target price of $1,018.75, suggesting a potential upside of 39,850.98%. Given KALA BIO's stronger consensus rating and higher probable upside, research analysts clearly believe KALA BIO is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

KALA BIO beats Lunai Bioworks on 8 of the 12 factors compared between the two stocks.

How does Lunai Bioworks compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

71.4% of Lunai Bioworks shares are held by institutional investors. 72.4% of eXoZymes shares are held by company insiders. Comparatively, 0.5% of Lunai Bioworks shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, eXoZymes and eXoZymes both had 1 articles in the media. eXoZymes' average media sentiment score of 0.00 equaled Lunai Bioworks'average media sentiment score.

Company	Overall Sentiment
eXoZymes	Neutral
Lunai Bioworks	Neutral

eXoZymes has higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than eXoZymes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	896.46	-$9.16M	-$1.14	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

eXoZymes' return on equity of -220.63% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%

eXoZymes has a beta of 2.65, suggesting that its stock price is 165% more volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

Summary

eXoZymes beats Lunai Bioworks on 7 of the 9 factors compared between the two stocks.

How does Lunai Bioworks compare to BeyondSpring?

Lunai Bioworks (NASDAQ:LNAI) and BeyondSpring (NASDAQ:BYSI) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Lunai Bioworks and Lunai Bioworks both had 1 articles in the media. BeyondSpring's average media sentiment score of 1.87 beat Lunai Bioworks' score of 0.00 indicating that BeyondSpring is being referred to more favorably in the news media.

Company	Overall Sentiment
Lunai Bioworks	Neutral
BeyondSpring	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lunai Bioworks has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market.

BeyondSpring has higher revenue and earnings than Lunai Bioworks. BeyondSpring is trading at a lower price-to-earnings ratio than Lunai Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
BeyondSpring	$1.75M	37.60	-$1.01M	-$0.14	N/A

BeyondSpring's return on equity of 0.00% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
BeyondSpring	N/A	N/A	-14.00%

Summary

BeyondSpring beats Lunai Bioworks on 8 of the 10 factors compared between the two stocks.

Get Lunai Bioworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LNAI vs. The Competition

Export

Metric	Lunai Bioworks	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$15.55M	$768.77M	$4.33B	$12.27B
Dividend Yield	N/A	4.84%	11.45%	5.88%
P/E Ratio	-8.90	1.43	21.93	23.97
Price / Sales	N/A	118.23	154.47	100.50
Price / Cash	N/A	20.06	38.01	53.91
Price / Book	-0.36	7.95	14.74	6.32
Net Income	-$178.01M	-$4.05M	$115.37M	$337.22M
7 Day Performance	-5.82%	-0.26%	-1.63%	-1.23%
1 Month Performance	68.72%	0.56%	-2.82%	-0.63%
1 Year Performance	N/A	45.81%	11.32%	27.95%

Lunai Bioworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LNAI Lunai Bioworks	0.1955 of 5 stars	$3.56 +3.8%	N/A	N/A	$15.55M	N/A	N/A	20
CING Cingulate	3.6177 of 5 stars	$5.01 +0.3%	$27.33 +446.0%	+15.8%	$67.21M	N/A	N/A	20	Positive News
ACRV Acrivon Therapeutics	1.7405 of 5 stars	$1.57 flat	$11.67 +643.1%	+18.8%	$67.20M	N/A	N/A	58
KALA KALA BIO	2.5195 of 5 stars	$3.61 flat	$1,018.75 +28,120.2%	-98.9%	$67.11M	N/A	N/A	30	High Trading Volume
EXOZ eXoZymes	0.4726 of 5 stars	$7.83 flat	N/A	-27.7%	$66.39M	$70K	N/A	29	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LNAI) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lunai Bioworks (LNAI) Competitors

LNAI vs. CING, ACRV, KALA, EXOZ, and BYSI

How does Lunai Bioworks compare to Cingulate?

Summary

How does Lunai Bioworks compare to Acrivon Therapeutics?

Summary

How does Lunai Bioworks compare to KALA BIO?

Summary

How does Lunai Bioworks compare to eXoZymes?

Summary

How does Lunai Bioworks compare to BeyondSpring?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI vs. The Competition

Lunai Bioworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lunai Bioworks (LNAI) Competitors

LNAI vs. CING, ACRV, KALA, EXOZ, and BYSI

How does Lunai Bioworks compare to Cingulate?

Do analysts prefer LNAI or CING?

Is LNAI or CING more profitable?

Which has higher earnings & valuation, LNAI or CING?

Which has more volatility and risk, LNAI or CING?

Does the media refer more to LNAI or CING?

Do institutionals and insiders have more ownership in LNAI or CING?

Summary

How does Lunai Bioworks compare to Acrivon Therapeutics?

Which has better earnings and valuation, ACRV or LNAI?

Do analysts prefer ACRV or LNAI?

Does the media favor ACRV or LNAI?

Do insiders and institutionals hold more shares of ACRV or LNAI?

Which has more risk & volatility, ACRV or LNAI?

Is ACRV or LNAI more profitable?

Summary

How does Lunai Bioworks compare to KALA BIO?

Do institutionals and insiders hold more shares of KALA or LNAI?

Is KALA or LNAI more profitable?

Which has preferable earnings & valuation, KALA or LNAI?

Does the media favor KALA or LNAI?

Which has more risk and volatility, KALA or LNAI?

Do analysts rate KALA or LNAI?

Summary

How does Lunai Bioworks compare to eXoZymes?

Do institutionals & insiders hold more shares of EXOZ or LNAI?

Does the media refer more to EXOZ or LNAI?

Which has stronger valuation & earnings, EXOZ or LNAI?

Do analysts rate EXOZ or LNAI?

Is EXOZ or LNAI more profitable?

Which has more risk & volatility, EXOZ or LNAI?

Summary

How does Lunai Bioworks compare to BeyondSpring?

Do insiders & institutionals hold more shares of LNAI or BYSI?

Does the media refer more to LNAI or BYSI?

Do analysts rate LNAI or BYSI?

Which has more volatility & risk, LNAI or BYSI?

Which has better earnings and valuation, LNAI or BYSI?

Is LNAI or BYSI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI vs. The Competition

Lunai Bioworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools